Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11526 posts found.

Monitor needs more clarity or risks failure – King’s Fund

November 10, 2011 Sales and Marketing Monitor, NHS reform, king's fund

The watchdog that will oversee competition and co-operation within the NHS needs to have a clearer remit or could face …
News
Circle logo

Private firm in NHS hospital takeover

November 10, 2011 Sales and Marketing Circle Healthcare, Hinchingbrooke, NHS

Circle Healthcare has sealed a deal to take over the running of a debt-ridden NHS hospital in Cambridgeshire. Private firms …
News

NICE won’t back Faslodex in breast cancer

November 10, 2011 Sales and Marketing AstraZeneca, Faslodex, NICE

NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …
News

Boehringer hails hepatitis C candidate

November 9, 2011 Sales and Marketing BI201335, Boehringer Ingelheim, HCV, Incivo, Victrelis, hepatitis C

Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …
News
Roche pic

Roche’s skin cancer drug receives FDA priority review

November 9, 2011 Research and Development, Sales and Marketing Roche, vismodegib

Roche’s skin cancer pill vismodegib will receive a priority review from the FDA which could see it approved within six …
News

Timothy Wright appointed as global head of development at Novartis Pharmaceuticals

November 9, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis

Novartis has appointed Dr Timothy Wright as the new global head of development of its pharmaceuticals business, effective immediately.  Dr …
Appointment

Edge Medical Communications makes two senior appointments

November 9, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Edge Medical, Medical comms

Edge Medical Communications has appointed Dr Laurence De-Netto as account director and Dr Elizabeth Rapley as business development manager. Dr …
Appointment
Lilly HQ picture

Amylin to pay up to $1.6 billion to sever ties with Lilly

November 8, 2011 Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, R&D, lilly

Amylin will pay up to $1.6 billion to end its diabetes pact with Lilly after a difficult year for the …
News

Strategic alliance executives

November 8, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CTPartners, Strategic alliance executives

Given the extraordinary costs and risks associated with drug discovery and development, it’s not surprising that an increasing number of …
Feature

AZ and Targacept’s novel depression drug misses target

November 8, 2011 Research and Development, Sales and Marketing AstraZeneca

AstraZeneca and Targacept’s next generation depression drug has failed to meet its primary endpoint in a late-stage trial. The first …
News

Organising a successful event

November 8, 2011 Sales and Marketing

Company conferences and events have come a long way since we used to be taken out for a short meeting …
Feature
Thought Leadership

Market access – looking back

November 8, 2011 Sales and Marketing

Market access is complicated. Multifaceted, multi-discipline, multidimensional, multi-stake-holder, all these multiples make Market Access one of the most challenging and …
Feature
Thought Leadership

Daniel Grau appointed as president of Heptares

November 8, 2011 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Daniel Grau, Heptares

Daniel Grau has been appointed as president of Heptares Therapeutics, a specialist in G-protein-coupled receptors.  Mr Grau has been a …
Appointment

GSK taps Alnylam tech for vaccine production

November 7, 2011 Manufacturing and Production, Sales and Marketing Alnylam, GSK, vaccines

GlaxoSmithKline has teamed up with gene silencing specialist Alnylam Pharmaceuticals in a project aimed at speeding up the production of …
News
david_roblin__picture_o

Ex-Pfizer R&D head Dr David Roblin joins Destiny Pharma

November 7, 2011 Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Destiny Pharma, Pfizer, R&D

Anti-microbial drug developers Destiny Pharma have appointed Dr David Roblin as its new medical director. Dr Roblin was formerly head …
Appointment
The Gateway to Local Adoption Series

Latest content

SMC accepts amivantamab and lazertinib for EGFR-positive lung cancer

May 22, 2026

BioDuro and CTI Biotechnology in preclinical drug development partnership

May 21, 2026

Sygnature Discovery appoints Susanne Back as Head of In Vivo Pharmacology

May 21, 2026

NICE recommends sotatercept for pulmonary arterial hypertension

May 20, 2026

Vetter begins construction of new injectable medicines facility

May 20, 2026